Literature DB >> 21169029

The impact of surgical ablation in patients with low ejection fraction, heart failure, and atrial fibrillation.

Niv Ad1, Linda Henry, Sharon Hunt.   

Abstract

OBJECTIVE: Surgical ablation procedures that use the Cox-Maze procedure lesion set were shown to be very effective. However, many surgeons are reluctant to perform the procedure, especially in high-risk patients such as those with reduced left ventricular (LV) function. This study explored the potential impact of the Cox-Maze III/IV procedure on patients with low ejection fraction (EF<40%) and symptoms of heart failure experiencing atrial fibrillation (AF) who present for cardiac surgery.
METHODS: A prospective study whereby patients with persistent or long-standing persistent AF who had surgical ablation were followed. Echocardiograms (echo) were obtained; patients with preoperative EF <40% were included. Health-related quality of life (HRQL-SF-12) and AF symptom severity were obtained at baseline and follow-up. Rhythm was captured by electrocardiogram (EKG) and 24-h Holter.
RESULTS: In the past 5 years, 482 patients had surgical ablation (424 full Cox-Maze) of whom 44 patients met the inclusion criteria; however, two patients did not have an available follow-up echo, leaving 42 patients for analysis. Mean age was 61.1 ± 12.9 years, and additive European System for Cardiac Operative Risk Evaluation (EuroSCORE) of 7.5 ± 3.1. There was one operative death, there were no strokes or transient ischemic attacks (TIAs) at follow-up, and EF improved from 30 ± 5.0% to 45 ± 13.0% at a mean of 1.5 ± 11.3 months, postoperatively. The return to NSR at time of follow-up echo was 86% (35/40). The physical functioning HRQL scores improved (37.0 ± 12.3 to 46.8 ± 9.1, p = 0.02) at 12 months (population norm = 38.1 ± 9.9) with a significant improvement in symptom severity. Kaplan-Meier event-free survival at 24 months was 87% (confidence interval (CI): 80.4-91.6) (events considered were redo valve replacement, ventricular assist device or death).
CONCLUSIONS: This is a unique study assessing a high-risk group of patients. Surgical ablation in patients with low EF can be performed in a safe and effective way without added operative risk. Given the potential long-term clinical advantages of a successful surgical ablation in patients with low EF and heart failure, we believe that surgical ablation should be considered in such patients when they present to surgery.
Copyright © 2010. Published by Elsevier B.V.

Entities:  

Mesh:

Year:  2010        PMID: 21169029     DOI: 10.1016/j.ejcts.2010.11.016

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  15 in total

1.  Performance of the Cox Maze procedure-a large surgical ablation center's experience.

Authors:  Linda Henry; Niv Ad
Journal:  Ann Cardiothorac Surg       Date:  2014-01

2.  Atrial fibrillation in heart failure: The sword of Damocles revisited.

Authors:  Muhammad A Khan; Fozia Ahmed; Ludwig Neyses; Mamas A Mamas
Journal:  World J Cardiol       Date:  2013-07-26

Review 3.  Minimally invasive surgery for atrial fibrillation.

Authors:  Michael O Zembala; Piotr Suwalski
Journal:  J Thorac Dis       Date:  2013-11       Impact factor: 2.895

4.  Combined management of atrial fibrillation and heart failure: case studies.

Authors:  Frederik H Verbrugge; Wilfried Mullens
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

5.  Results of clinical application of the modified maze procedure as concomitant surgery.

Authors:  Robbert C Bakker; Sakir Akin; Dimitris Rizopoulos; Charles Kik; Johanna J M Takkenberg; Ad J J C Bogers
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-10-26

Review 6.  Atrial fibrillation in heart failure: catheter and surgical interventional therapies.

Authors:  Ali Rabah; Oussama Wazni
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

7.  Atrial fibrillation in patients with systolic heart failure: pathophysiology mechanisms and management.

Authors:  Ioanna Koniari; Eleni Artopoulou; Dimitrios Velissaris; Nicholas Kounis; Grigorios Tsigkas
Journal:  J Geriatr Cardiol       Date:  2021-05-28       Impact factor: 3.327

Review 8.  Targeting inflammation and oxidative stress in atrial fibrillation: role of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibition with statins.

Authors:  Ana Catarina Pinho-Gomes; Svetlana Reilly; Ralf P Brandes; Barbara Casadei
Journal:  Antioxid Redox Signal       Date:  2013-10-19       Impact factor: 8.401

Review 9.  Atrial fibrillation in heart failure: an innocent bystander?

Authors:  M A Khan; L Neyses; M A Mamas
Journal:  Curr Cardiol Rev       Date:  2012-11

Review 10.  Atrial fibrillation in heart failure: what should we do?

Authors:  Dipak Kotecha; Jonathan P Piccini
Journal:  Eur Heart J       Date:  2015-09-28       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.